Search Results - "van Pel, M."

An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development by van Pel, Derek M, Barrett, Irene J, Shimizu, Yoko, Sajesh, Babu V, Guppy, Brent J, Pfeifer, Tom, McManus, Kirk J, Hieter, Philip

“…Harnessing genetic differences between cancerous and noncancerous cells offers a strategy for the development of new therapies. Extrapolating from yeast…”
Get full text

Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition by Bailey, Melanie L, O'Neil, Nigel J, van Pel, Derek M, Solomon, David A, Waldman, Todd, Hieter, Philip

“…Recent data have identified STAG2, a core subunit of the multifunctional cohesin complex, as a highly recurrently mutated gene in several types of cancer. We…”
Get full text

Synthetic lethality and cancer: cohesin and PARP at the replication fork by O’Neil, Nigel J, van Pel, Derek M, Hieter, Philip

“…Highlights ► Synthetic lethal networks in yeast identify clinically relevant genetic interactions. ► Cohesins are recurrently mutated in a variety of tumor…”
Get full text

Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications by Staal, F J T, Baum, C, Cowan, C, Dzierzak, E, Hacein-Bey-Abina, S, Karlsson, S, Lapidot, T, Lemischka, I, Mendez-Ferrer, S, Mikkers, H, Moore, K, Moreno, E, Mummery, C L, Robin, C, Suda, T, Van Pel, M, Vanden Brink, G, Zwaginga, J J, Fibbe, W E

“…The hematopoietic stem cell (HSC) is the prototype organ-regenerating stem cell (SC), and by far the most studied type of SC in the body. Currently, HSC-based…”
Get full text

Synthetic lethality of cohesins with PARPs and replication fork mediators by McLellan, Jessica L, O'Neil, Nigel J, Barrett, Irene, Ferree, Elizabeth, van Pel, Derek M, Ushey, Kevin, Sipahimalani, Payal, Bryan, Jennifer, Rose, Ann M, Hieter, Philip

“…Synthetic lethality has been proposed as a way to leverage the genetic differences found in tumor cells to affect their selective killing. Cohesins, which…”
Get full text

Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro by Calkoen, F.G.J., Vervat, C., van Pel, M., de Haas, V., Vijfhuizen, L.S., Eising, E., Kroes, W.G.M., 't Hoen, P.A.C., van den Heuvel-Eibrink, M.M., Egeler, R.M., van Tol, M.J.D., Ball, L.M.

“…Pediatric myelodysplastic syndrome (MDS) is a heterogeneous disease covering a spectrum ranging from aplasia (RCC) to myeloproliferation (RAEB(t)). In…”
Get full text

The MADD-3 LAMMER Kinase Interacts with a p38 MAP Kinase Pathway to Regulate the Display of the EVA-1 Guidance Receptor in Caenorhabditis elegans by D'Souza, Serena A, Rajendran, Luckshi, Bagg, Rachel, Barbier, Louis, van Pel, Derek M, Moshiri, Houtan, Roy, Peter J

“…The proper display of transmembrane receptors on the leading edge of migrating cells and cell extensions is essential for their response to guidance cues. We…”
Get full text

Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers by VAN PEL, M, VAN BREUGEL, D W J G, VOS, W, PLOEMACHER, R. E, BOOG, C. J. P

“…Treosulfan is a water-soluble structural analog of busulfan, acting as a prodrug of alkylating epoxide species. It does not induce severe hepatotoxicity or…”
Get full text

Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers by VAN PEL, M, VAN BREUGEL, Dwjg, VOS, W, PLOEMACHER, R. E, BOOG, C. J. P

“…To investigate whether we could create a radiation-free conditioning regimen to induce permanent mixed and multilineage chimerism and donor-specific tolerance,…”
Get full text

Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma by van Pel, Derek M., Cheung, Simon, Ionescu, Diana N., Churg, Andrew

“…Distinguishing mesothelioma from non–small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in…”
Get full text

P1361: TREATMENT OF SEVERE STEROID‐REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE‐BLIND MULTI‐CENTER HOVON‐113 TRIAL by Oosten, L., Pel, M., Holt, B., Bach, E., Cross, M., Roelofs, H., Meij, P., Wieles, B., Zwaginga, J. J., Lankester, A., Veelken, H., Platzbecker, U., Sanchez‐Guijo, F., Algeri, M., Locatelli, F., Devos, T., Cornelissen, J., Niederwieser, D., Fibbe, W.

Get full text

Modelling glioma invasion using 3D bioprinting and scaffold-free 3D culture by van Pel, Derek M., Harada, Kaori, Song, Dandan, Naus, Christian C., Sin, Wun Chey

“…Glioma is a highly aggressive form of brain cancer, with some subtypes having 5-year survival rates of less than 5%. Tumour cell invasion into the surrounding…”
Get full text

Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma by van Pel, Derek M., Pors, Jennifer, Yuen, Eddie, Chan, Rebecca, Kos, Zuzana, Hayes, Malcolm M., Wang, Gang

“…Uroplakin II (UPII) has been shown as a highly specific marker of urothelial carcinoma; however, it can also stain subtypes of apocrine-differentiated breast…”
Get full text

Process Development and Manufacturing: DESIGNING, BUILDING AND COMMISSIONING A MULTI-PRODUCT CELL AND GENE THERAPY CLEANROOM FACILITY: LESSONS LEARNED by van Pel, M., Pritchard-Meaker, T.

Get full text

6 - Process Development and Manufacturing: DESIGNING, BUILDING AND COMMISSIONING A MULTI-PRODUCT CELL AND GENE THERAPY CLEANROOM FACILITY: LESSONS LEARNED by van Pel, M., Pritchard-Meaker, T.

Get full text

Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork by van Pel, Derek M, Stirling, Peter C, Minaker, Sean W, Sipahimalani, Payal, Hieter, Philip

“…The concept of synthetic lethality has gained popularity as a rational guide for predicting chemotherapeutic targets based on negative genetic interactions…”
Get full text

A comparison of chondrogenesis oriented differentiating protocols for induced pluripotent stem cells by Ruiz, A. Rodriguez, van Hoolwerff, M., Koen, S., van Pel, M., Nelissen, R.G., Meulenbelt, I., Ramos, Y.F.

Get full text

Comparability of MSC manufacturing protocols for clinical trials by van Pel, M., Steeneveld, E., van den Broeke, L., Kortekaas, S., de Hoop, T.D., Fibbe, W., Zwaginga, J.

“…Mesenchymal stromal cells (MSC) are clinically applied for their immunomodulatory and regenerative capacities. Despite promising results, comparison of the…”
Get full text

P363 Locally injected allogeneic bone marrow-derived mesenchymal stromal cells for the treatment of refractory proctitis: clinical results of a phase IIa trial by Ouboter, L, Barnhoorn, M, van Pel, M, Zwaginga, J J, Hawinkels, L, Maljaars, J, Koning, F, Verspaget, H, van der Meulen - de de Jong, A

“…Abstract Background Ulcerative proctitis (UP) can be refractory to treatment, which calls for development of new (local) therapies. Local injection of…”
Get full text

DOP64 Endoscopically injected allogeneic mesenchymal stromal cells alter the mucosal immune cell compartment in patients with ulcerative proctitis by Ouboter, L, Barnhoorn, M, Plug, L, van Pel, M, Zwaginga, J J, Roelen, D, Pascutti, F, Koning, F, Hawinkels, L, Verspaget, H, van der Meulen - de Jong, A

“…Abstract Background Local mesenchymal stromal cell (MSC)-therapy is approved for the treatment of Crohn’s disease-associated perianal fistulas. However, little…”
Get full text